|
|
|
|
|
|
|
|
|
12.06.26 - 11:39
|
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) (GlobeNewswire EN)
|
|
|
Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido® (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a global Phase III CIndU clinical trial7. In the RemIND trial, higher rates of complete responses were observed at week 12, with responses seen as early as week 2 in two subtypes. These results demonstrate that Rhapsido may provide sustained relief for patients whose disease remains inadequately controlled after treatment with second-generation H1-antihistamines7.“Chronic inducible urticaria (CIndU) is a form of chronic hives in which everyday triggers—such as pressure, heat, cold, or sunlight—can lead to itchy wheals, and there are currently no approved targeted treatment options,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of All...
|
|
|
|
|
|
|
|
|
|
|
11.06.26 - 10:31
|
Novartis Hold (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Novartis auf "Hold" mit einem Kursziel von 110 Franken belassen. Die Biomarker-Daten der FORTITUDE-Studie mit Delpacibart braxlosiran (Del-prax) bei Fazioskapulohumeraler Muskeldystrophie ......
|
|
|
|
|
|
|
|
|
09.06.26 - 15:03
|
Blue Matter Expands Capabilities in Healthcare Policy Support for Life Sciences Led by Partner, Milena Sullivan (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of an expanded policy capability to support biopharma clients, led by Milena Sullivan, a Partner who joined the firm in December 2025.
Milena Sullivan brings more than 20 years of experience in healthcare policy, advocacy, and market access, advising life science companies, trade associations, and provider organizations on policy issues shaping their business. Prior to joining Blue Matter, she spent almost a decade with Avalere Health, where most recently she led the policy practice. She has also held in-house policy roles at Bristol-Myers Squibb and Novartis Vaccines and Diagnostics, as well as policy positions in the nonprofit space, including at the Center for Strategic and International Studies (CSIS). She holds an MA in International Policy and Practice from The George Washington University and a BA from Miami University of Ohio.
At Blue Matter, Milena is leading a policy capability that integrates directly into the firm's broad range...
|
|
|
09.06.26 - 10:12
|
Novartis Buy (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis mit einem Kursziel von 135 Franken auf "Buy" belassen. Dies schrieb Emmanuel Papadakis in seinem am Dienstag vorliegenden Kommentar zu den wöchentlichen Verschreibungszahlen./rob/ag/laVeröffentlichung ......
|
|
|
|
|
08.06.26 - 09:03
|
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 (GlobeNewswire EN)
|
|
|
Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido® (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urt...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
